ReviewPeritoneal dialysis international : journal of the International Society for Peritoneal Dialysis2020
Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy.
Review in Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Effects of Intravenous Administration of Vancomycin on Peritonitis in a Patient on Peritoneal Dialysis.Clinical case reports · 2025Article
- The association between empirical antibiotic regimens and the outcome of peritoneal dialysis-related peritonitis: a multi-center, large-scale cohort study.Journal of nephrology · 2025Article
- Article
- Simplifying Antibiotic Management of Peritonitis in APD: Evidence from a Non-Inferiority Randomized Trial.Antibiotics (Basel, Switzerland) · 2025Article
- Unveiling the drivers of vancomycin-resistant enterococcus in China: A comprehensive ecological study.Infectious medicine · 2025Article
- Hemodialysis treatment of vancomycin-induced drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome in a patient undergoing peritoneal dialysis.CEN case reports · 2024Article
- Linking clinical manifestations and causative organisms may provide clues for the treatment of peritoneal dialysis-associated peritonitis.BMC nephrology · 2024Article
- The Association Between Serum Vancomycin Level and Clinical Outcome in Patients With Peritoneal Dialysis Associated Peritonitis.Kidney international reports · 2023Article
- Antimicrobial-loaded biodegradable nanoemulsions for efficient clearance of intracellular pathogens in bacterial peritonitis.Biomaterials · 2023Article
- First Case Report of Peritoneal Dialysis-associated Peritonitis Caused by Lysinibacillus sphaericus.Internal medicine (Tokyo, Japan) · 2023Article
- Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis.Clinical and translational science · 2022Article
- The Correlation between Serum Sclerostin Level and Arterial Stiffness in Peritoneal Dialysis Patients.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Pharmacokinetics of Intraperitoneal Vancomycin and Amikacin in Automated Peritoneal Dialysis Patients With Peritonitis.Frontiers in pharmacology · 2021Article
- Intraperitoneally Administered Vancomycin Results in Suboptimal Serum and Peritoneal Effluent Drug Levels in Patients with PD-related Peritonitis.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Intraperitoneal vancomycin is the first-line therapy in the management of peritoneal dialysis (PD)-related peritonitis. However, due to the paucity of data, vancomycin dosing for peritonitis in patients on automated peritoneal dialysis (APD) is empiric and based on clinical experience rather than evidence. Studies in continuous ambulatory peritoneal dialysis (CAPD) patients have been used to provide guidelines for dosing and are often extrapolated for APD use, but it is unclear whether this is appropriate. This review summarizes the available pharmacokinetic data used to inform optimal dosing in patients on CAPD or APD. The determinants of vancomycin disposition and pharmacodynamic effects are critically summarized, knowledge gaps explored, and a vancomycin dosing algorithm in PD patients is proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.